Condition
Sedation in the ICU
Total Trials
4
Recruiting
0
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Completed3
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07579390Not ApplicableActive Not Recruiting
Effects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE)
NCT06222294Phase 3CompletedPrimary
A Study of Remimazolam Tosilate for Sedation in the ICU
NCT05913336Phase 1CompletedPrimary
A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU
NCT05152303Phase 2CompletedPrimary
A Study of Remimazolam Tosilate for Sedation in the ICU
Showing all 4 trials